Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
"Dr. Staedtke's Lab is interested in the identification and understanding of mechanisms contributing to immune-mediated toxicity and anti-tumor response following immunotherapy. They recently identified that catecholamines that are produced by stress-exposed immune cells drive CART-induced immunotoxicities, and that blocking catecholamine production reduced Cytokine Release Syndrome (CRS) and also enhanced tumor killing. They propose to use these findings to help overcome some of the existing challenges in brain cancer immunotherapy by exploring the role of catecholamines in immunotoxicity and on CART anti-tumor actions in the brain. If successful, these results will advance the mechanistic understanding, reduce immunotoxicity, and ultimately create novel brain-specific immunotherapeutic agents that will improve patient outcomes."